Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation v
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL
Immix Biopharma Announces 12-Month Progress Update Including Shareholder Letter
Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder le
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and
Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In AL Amyloidosis
European Orphan Drug Designation ("ODD") qualifies NXC-201 for:10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol
Immix Biopharma Announces New Offering, Sparks Investor Interest
Immix Biopharma Signs Definitive $15M Titan Partnership Deal
PRSO, AKRO and MIRA Among Pre-market Losers
Immix Biopharma Suspends Stock Offering Pending New Prospectus
Immix Biopharma Prices $15 Million Stock Offering
Immix Biopharma (IMMX) said late Monday it priced an underwritten public offering of approximately 5.5 million shares of common stock at $2.71 per share for expected gross proceeds of $15 million. The
Immix Biopharma: Titan Partners Group, a Division of American Capital Partners, Is Sole Bookrunning Manager for Offering >IMMX
Immix Biopharma: Titan Partners Group, a Division of American Capital Partners, Is Sole Bookrunning Manager for Offering >IMMX
Immix Is a Clinical-Stage Biopharmaceutical Co Developing Cell Therapies in Autoimmune Disease >IMMX
Immix Is a Clinical-Stage Biopharmaceutical Co Developing Cell Therapies in Autoimmune Disease >IMMX
Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma Expects Gross Proceeds of About $15M From Offering >IMMX
Immix Biopharma Expects Gross Proceeds of About $15M From Offering >IMMX
Immix Biopharma Prices Public Offering of 5.5M Shares at $2.71 Each >IMMX
Immix Biopharma Prices Public Offering of 5.5M Shares at $2.71 Each >IMMX
Immix Biopharma Grants Underwriters Option to Buy Up to 783,970 Additional Shares >IMMX
Immix Biopharma Grants Underwriters Option to Buy Up to 783,970 Additional Shares >IMMX
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and
Immix Biopharma Proposes Stock Offering; Shares Slump
Immix Biopharma (IMMX) said late Monday it plans to sell shares in an underwritten public offering to raise funds for NXC-201 clinical trials, working capital and general corporate purposes. Immix Bio
No Data